Authors
Berkeley N Limketkai, Shruti H Mehta, Catherine G Sutcliffe, Yvonne M Higgins, Michael S Torbenson, Sherilyn C Brinkley, Richard D Moore, David L Thomas, Mark S Sulkowski
Publication date
2012/7/25
Journal
Jama
Volume
308
Issue
4
Pages
370-378
Publisher
American Medical Association
Description
Context
Human immunodeficiency virus (HIV) accelerates hepatitis C virus (HCV) disease progression; however, the effect of liver disease stage and antiviral therapy on the risk of clinical outcomes is incompletely understood.
Objective
To determine the incidence of end-stage liver disease (ESLD), hepatocellular carcinoma (HCC), or death according to baseline hepatic fibrosis and antiviral treatment for HIV/HCV coinfected individuals.
Design, Setting, and Participants
Prospective cohort of 638 coinfected adults (80% black, 66% men) receiving care at the Johns Hopkins HIV clinic and receiving a liver biopsy and who were prospectively monitored for clinical events between July 1993 and August 2011 (median follow-up, 5.82 years; interquartile range, 3.42-8.85 years). Histological specimens were scored for hepatic fibrosis stage according to the METAVIR scoring system.
Main Outcome Measure
Incidence of …
Scholar articles
BN Limketkai, SH Mehta, CG Sutcliffe, YM Higgins… - Jama, 2012